FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) is a licensed producer focused on building out a 3.9 million sq. ft. indoor hydroponic facility near Toronto capable of producing 400,000 kilograms of dried cannabis per year. With a newly acquired sales license and 25,000 sq. ft. already in production, the company is on the cusp of generating revenue through partnerships with its tenants where it’s entitled to royalty income on production.
CFN Media recently caught up with Chairman and CEO Dr. Raza Bokhari at the Arcview Investor Forum in Vancouver to discuss the company and its plans for 2019.
Licenses & Acquisitions
FSD Pharma recently appointed Dr. Sara May as President of FV Pharma Inc., the company’s licensed producer subsidiary. Dr. May is an experienced geneticist that brings a decade of experience designing, implementing, and managing large-scale research projects into the fold. Under her guidance, the company secured a much anticipated sales license for plants and seeds in April, which opens the door to near-term commercialization.
The company has also been active in expanding distribution channels for its medical cannabis products. In April, the company announced a share exchange with Aura Health Inc., an international network of vertically-integrated cannabis assets with a major presence in Europe. Management’s goal with the transaction is to expand its distribution footprint into Europe—a region that’s expected to see significant demand growth.
The company also recently announced the acquisition of Prismic Pharmaceuticals, a U.S.-based specialty pharmaceutical company led by a former founder of Shire plc, which was recently acquired for $60 billion. The acquisition fits within the company’s long-term ambitions to develop synthetic cannabinoids that could be approved by the U.S. FDA for the treatment of CNS disorders, pain management, and other indications.
Short- & Long-term Goals
FSD Pharma’s approach to the cannabis market differs from many other licensed producers. Rather than simply producing cannabis flower and oil, the company has focused on identifying ways to bring medicinal benefits to patients. Its indoor hydroponic facility is designed to ensure maximum quality, while partnerships with Canntab Therapeutics and Pharmastrip Corp. incorporate innovative new delivery methods.
Over the long-term, the company hopes to develop synthetic cannabinoid technologies that could translate to more predictable medicine, lower costs, and better patient outcomes. The company’s acquisition of Prismic Pharmaceuticals and letter of intent with Solarvest represents a step in this direction. Solarvest’s algae-based synthetic cannabinoid research could dramatically shorten the production time for specific cannabinoid molecules.
Dr. Bokhari mentions that the company also plans to list their stock on the New York Stock Exchange (NYSE), which could improve liquidity for existing shareholders and open the door to greater investment.
FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) has been making tremendous strides over the past few months after securing a sales license and making a number of strategic partnerships and acquisitions. Investors may want to keep an eye on the company as FSD continues to move closer to a commercial stage for medical cannabis production while simultaneously developing its pharmaceutical products.
For more information, visit the company’s website at www.fsdpharma.com.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/